Deze pagina is automatisch vertaald en de nauwkeurigheid van de vertaling kan niet worden gegarandeerd. Raadpleeg de Engelse versie voor een brontekst.

Operator-Assisted Oscilla Audiometry as a Basis for Hearing Aid Fitting (The Oscilla Validation Study)

15 november 2026 bijgewerkt door: Lene Dahl Siggaard, Aalborg University Hospital

Validation of Operator-Assisted Oscilla Audiometry as a Diagnostic Tool and Basis for Hearing Aid Fitting in Adults With Uncomplicated Hearing Loss: A Blinded Non-Inferiority Randomised Controlled Trial

The purpose of this study is to find out whether hearing tests performed with the Oscilla A60 audiometer, where the patient largely tests themselves with minimal staff assistance, are accurate enough to be used for diagnosing hearing loss and as the sole basis for fitting hearing aids. Adults referred for their first hearing aids at Aalborg University Hospital will have their hearing tested both with the Oscilla audiometer and by a trained audiology assistant at the same visit. Participants are then randomly assigned to receive hearing aids fitted based on either the Oscilla hearing test or the audiology assistant's hearing test. The main questions are: (1) Do the Oscilla results agree with the audiology assistant's results for both air-conduction and bone-conduction hearing thresholds? (2) Do participants fitted based on the Oscilla test report a hearing benefit that is not worse than that of participants fitted based on the standard test, two months after fitting?

Studie Overzicht

Gedetailleerde beschrijving

Demand for audiometric testing in public hearing clinics is increasing due to population ageing. Operator-assisted automated audiometry may expand capacity, but its use as the sole basis for hearing aid prescription, and its accuracy for bone-conduction (BC) thresholds, has not been established. This single-site study at the Department of Audiology, Aalborg University Hospital (locations in Aalborg and Hobro) enrols 268 first-time hearing aid users with uncomplicated, symmetric sensorineural hearing loss.

At Visit 1, all participants undergo both Oscilla A60 audiometry (air conduction [AC] 250-8000 Hz; BC 250-4000 Hz) and standard manual audiometry by an audiology assistant (reference standard), in randomised order. Agreement between methods is assessed with Bland-Altman analysis against pre-specified acceptance criteria (95% CI of bias within ±5 dB; 95% limits of agreement within ±15 dB for AC and ±20 dB for BC). After confirmation of eligibility, participants are randomised 1:1, stratified by hearing loss severity (PTA-4 ≤45 vs >45 dB HL) and location, to hearing aid fitting based on the Oscilla audiogram or the audiology assistant audiogram. All participants are fitted bilaterally with BTE/RIC hearing aids to the NAL-NL2 target, verified with automated real-ear measurements (within ±5 dB). Volume control and app connectivity are disabled until the two-month follow-up. The primary patient-reported outcome is the change in SSQ12 total score from baseline to two months post-fitting, with a non-inferiority margin of -0.81 points. Secondary outcomes are IOI-HA, daily hearing aid use (data logging) and SSQ12 subscales. The study is a clinical investigation under Article 82 of Regulation (EU) 2017/745.

Studietype

Ingrijpend

Inschrijving (Geschat)

268

Fase

  • Niet toepasbaar

Contacten en locaties

In dit gedeelte vindt u de contactgegevens van degenen die het onderzoek uitvoeren en informatie over waar dit onderzoek wordt uitgevoerd.

Studiecontact

  • Naam: Lene D Siggaard, MD, PhD
  • Telefoonnummer: +45 20633492
  • E-mail: lene.dahl@rn.dk

Studie Contact Back-up

Studie Locaties

      • Aalborg, Denemarken, 9000
        • Department of Audiology, Aalborg University Hospital
        • Contact:
        • Contact:
          • Lene D Siggaard, MD, PhD
          • Telefoonnummer: +4520633492
          • E-mail: lene.dahl@rn.dk
      • Hobro, Denemarken, 9500
        • Hearing Clinic, Aalborg University Hospital
        • Contact:
        • Contact:
          • Lene D Siggaard, MD, PhD
          • Telefoonnummer: +4520633492
          • E-mail: lene.dahl@rn.dk

Deelname Criteria

Onderzoekers zoeken naar mensen die aan een bepaalde beschrijving voldoen, de zogenaamde geschiktheidscriteria. Enkele voorbeelden van deze criteria zijn iemands algemene gezondheidstoestand of eerdere behandelingen.

Geschiktheidscriteria

Leeftijden die in aanmerking komen voor studie

18 jaar en ouder (Volwassen, Oudere volwassene)

Accepteert gezonde vrijwilligers

Nee

Geslachten die in aanmerking komen voor studie

Allemaal

Beschrijving

Inclusion Criteria:

  • Adults (≥18 years) referred for first-time hearing aid fitting at the Department of Audiology, Aalborg University Hospital
  • Uncomplicated sensorineural hearing loss as defined by the Danish national clinical guidelines
  • Hearing thresholds exceeding 20 dB HL at two or more frequencies in the range 0.5-4 kHz
  • Pure-tone average (PTA-4; 0.5, 1, 2, 4 kHz) ≥30 dB HL in the better ear
  • Symmetric hearing loss (PTA-4 difference between ears ≤15 dB)
  • Word discrimination score ≥25% (DANTALE I at PTA + 40 dB HL)
  • Danish native speaker
  • No prior hearing aid experience
  • Able to complete questionnaires online or on paper
  • Written informed consent

Exclusion Criteria:

  • Air-conduction thresholds exceeding 80 dB HL at two or more frequencies
  • Air-bone gap >15 dB at one or more frequencies below 1 kHz
  • Fluctuating hearing loss (e.g., Ménière's disease) or ongoing ototoxic medication
  • Ear surgery (ear canal, middle ear or inner ear) within the past 12 months
  • Hearing loss classified as complicated according to national clinical guidelines
  • Visual or motor impairment precluding independent use of the Oscilla system
  • Candidates for in-the-ear hearing aids only (all participants are fitted with BTE or RIC hearing aids)

Studie plan

Dit gedeelte bevat details van het studieplan, inclusief hoe de studie is opgezet en wat de studie meet.

Hoe is de studie opgezet?

Ontwerpdetails

  • Primair doel: Diagnostisch
  • Toewijzing: Gerandomiseerd
  • Interventioneel model: Parallelle opdracht
  • Masker: Enkel

Wapens en interventies

Deelnemersgroep / Arm
Interventie / Behandeling
Experimenteel: Oscilla-based fitting

Hearing aids fitted bilaterally to NAL-NL2 targets based on the Oscilla A60 audiogram, verified with automated real-ear measurement. Volume control and app connectivity disabled for two months (linked interventions: Paired audiometry and Oscilla-based hearing aid fitting).

At Visit 1, all participants undergo both operator-assisted Oscilla A60 audiometry (AudioConsole v4.6.0; AC and BC thresholds; operator places the BC headband only) in a quiet room (<50 dB SPL) and manual pure-tone audiometry (AC and BC, ISO 8253-1) by a qualified audiology assistant in a sound-attenuating booth, in randomised order.

Bilateral BTE/RIC hearing aid fitting to NAL-NL2 targets using the Oscilla A60 audiogram as the sole audiometric basis, verified with auto-REM (within ±5 dB of target). Other names: Oscilla A60 Diagnostic Audiometer.

Actieve vergelijker: Manual audiometry-based fitting

Hearing aids fitted bilaterally to NAL-NL2 targets based on the audiogram obtained by a qualified audiology assistant, verified with automated real-ear measurement. Volume control and app connectivity disabled for two months (linked interventions: paired audiometry and manual audiometry-based hearing aid fitting).

At Visit 1, all participants undergo both operator-assisted Oscilla A60 audiometry (AudioConsole v4.6.0; AC and BC thresholds; operator places the BC headband only) in a quiet room (<50 dB SPL) and manual pure-tone audiometry (AC and BC, ISO 8253-1) by a qualified audiology assistant in a sound-attenuating booth, in randomised order.

Bilateral BTE/RIC hearing aid fitting to NAL-NL2 targets using the audiology assistant audiogram, verified with auto-REM (within ±5 dB of target). Standard clinical practice.

Wat meet het onderzoek?

Primaire uitkomstmaten

Uitkomstmaat
Maatregel Beschrijving
Tijdsspanne
Agreement between Oscilla A60 and manual audiometry for air-conduction thresholds
Tijdsspanne: Visit 1 (Week 0)

Bland-Altman mean difference (Oscilla minus manual) and 95% limits of agreement in dB, plus mean absolute difference, at 0.5, 1, 2 and 4 kHz separately. Agreement is acceptable if the 95% CI of the bias is within ±5 dB and the 95% limits of agreement are within ±15 dB. Both ears included, clustering handled with a mixed-effects model.

Visit 1 (Week 0)
Agreement between Oscilla A60 and manual audiometry for bone-conduction thresholds
Tijdsspanne: Visit 1 (Week 0)

As above for bone-conduction thresholds at 0.5, 1, 2 and 4 kHz. Agreement is acceptable if the 95% CI of the bias is within ±5 dB and the 95% limits of agreement are within ±20 dB.

Visit 1 (Week 0)
Change in SSQ12 total score
Tijdsspanne: Baseline (Week 0) and 2 months after hearing aid fitting

Speech, Spatial and Qualities of Hearing Scale, 12-item version; total score = mean of 12 items, range 0-10, higher = better. Non-inferiority if the lower bound of the two-sided 95% CI for the between-group difference in change (Oscilla minus control) is above -0.81 points.

Baseline (Week 0) and 2 months after hearing aid fitting

Secundaire uitkomstmaten

Uitkomstmaat
Maatregel Beschrijving
Tijdsspanne
IOI-HA total score
Tijdsspanne: 2 months after hearing aid fitting

International Outcome Inventory for Hearing Aids, Danish version; 7 items scored 1-5, total range 7-35, higher = better outcome. Compared between groups

2 months after hearing aid fitting
Daily hearing aid use
Tijdsspanne: From hearing aid fitting to 2 months after fitting

Mean daily hearing aid usage time in hours/day from the hearing aid data log, compared between groups

From hearing aid fitting to 2 months after fitting
Change in SSQ12 subscale scores
Tijdsspanne: Baseline (Week 0) and 2 months after hearing aid fitting

Change in the speech, spatial and qualities subscale scores (each range 0-10, higher = better)

Baseline (Week 0) and 2 months after hearing aid fitting

Medewerkers en onderzoekers

Hier vindt u mensen en organisaties die betrokken zijn bij dit onderzoek.

Onderzoekers

  • Hoofdonderzoeker: Lene D Siggaard, MD, PhD, Department of Otolaryngology, Head- and Neck Surgery and Audiology, Aalborg University Hospital

Studie record data

Deze datums volgen de voortgang van het onderzoeksdossier en de samenvatting van de ingediende resultaten bij ClinicalTrials.gov. Studieverslagen en gerapporteerde resultaten worden beoordeeld door de National Library of Medicine (NLM) om er zeker van te zijn dat ze voldoen aan specifieke kwaliteitscontrolenormen voordat ze op de openbare website worden geplaatst.

Bestudeer belangrijke data

Studie start (Geschat)

1 december 2026

Primaire voltooiing (Geschat)

31 oktober 2027

Studie voltooiing (Geschat)

31 oktober 2027

Studieregistratiedata

Eerst ingediend

15 november 2026

Eerst ingediend dat voldeed aan de QC-criteria

15 november 2026

Eerst geplaatst (Werkelijk)

19 november 2026

Updates van studierecords

Laatste update geplaatst (Werkelijk)

19 november 2026

Laatste update ingediend die voldeed aan QC-criteria

15 november 2026

Laatst geverifieerd

1 november 2026

Meer informatie

Termen gerelateerd aan deze studie

Andere studie-ID-nummers

  • F2026-115
  • Regional Innovation Fund (Ander subsidie-/financieringsnummer: North Denmark Region)
  • Danish Medicines Agency (Register-ID: 16-0302-225)

Plan Individuele Deelnemersgegevens (IPD)

Bent u van plan om gegevens van individuele deelnemers (IPD) te delen?

ONBESLIST

Beschrijving IPD-plan

Pseudonymised individual participant data may be shared upon reasonable request after publication, subject to approval under the GDPR and Danish data protection law and a data processing agreement.

Informatie over medicijnen en apparaten, studiedocumenten

Bestudeert een door de Amerikaanse FDA gereguleerd geneesmiddel

Nee

Bestudeert een door de Amerikaanse FDA gereguleerd apparaatproduct

Nee

Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .

Abonneren